Publications

BibTex format

@article{Gentleman:2018:10.1007/978-1-4939-7704-8_18,
author = {Gentleman, S and Liu, AKL},
doi = {10.1007/978-1-4939-7704-8_18},
journal = {Methods Mol Biol},
pages = {271--279},
title = {Neuropathological Assessment as an Endpoint in Clinical Trial Design.},
url = {http://dx.doi.org/10.1007/978-1-4939-7704-8_18},
volume = {1750},
year = {2018}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Different neurodegenerative conditions can have complex, overlapping clinical presentations that make accurate diagnosis during life very challenging. For this reason, confirmation of the clinical diagnosis still requires postmortem verification. This is particularly relevant for clinical trials of novel therapeutics where it is important to ascertain what disease and/or pathology modifying effects the therapeutics have had. Furthermore, it is important to confirm that patients in the trial actually had the correct clinical diagnosis as this will have a major bearing on the interpretation of trial results. Here we present a simple protocol for pathological assessment of neurodegenerative changes.
AU  - Gentleman,S
AU  - Liu,AKL
DO  - 10.1007/978-1-4939-7704-8_18
EP  - 279
PY  - 2018///
SP  - 271
TI  - Neuropathological Assessment as an Endpoint in Clinical Trial Design.
T2  - Methods Mol Biol
UR  - http://dx.doi.org/10.1007/978-1-4939-7704-8_18
UR  - https://www.ncbi.nlm.nih.gov/pubmed/29512079
VL  - 1750
ER  -

Download

Dr Alan King Lun Liu

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)